Angiotensin-converting enzyme and converting enzyme inhibitors

Cellular and Molecular Biology of the Renin-Angiotensin System

Volumn , Issue , 2018, Pages 183-220

  Berecek, Kathleen H ^a   King, Steven J ^b   Wu, Jian N ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Department of Physiology and Biophysics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051617993     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781351070492     Document Type: Chapter

References (292)

1. Skeggs, L.T., Kahn, J.R., and Shumway, N.P., The preparation and function of the hypertensin-converting enzyme, J. Exp. Med., 103, 295, 1956.
2. Yang, H.Y.T., Erdos, E.G., and Levin, Y., A dipeptide carboxypeptidase that converts AI and inactivates bradykinin, Biochim. Biophys. Acta, 214, 374, 1970.
3. Erdos, E.G. and Skidgel, R.A., Structure and functions of human AI converting enzyme (kininase II), Biochem. Soc. Trans., 13, 42, 1985.
4. Ng, K.K.F. and Vane, J.R., Conversion of AI to All, Nature, 216, 762, 1967.
5. Stanley, P. and Biron, P., Pressor response to AI during cardiopulmonary bypass, Experientia, 26, 46, 1969.
6. Caldwell, P.R.B., Seegal, B.C., Hsu, K.C., Das, M., and Softer, R.L., Angiotensinconverting enzyme: vascular endothelial localization, Science, 191, 1050, 1976.
7. Ryan, U.S., Ryan, J.W., Whitaker, C., and Chiu, A., Localization of ACE (kininase II). II. Immunocytochemistry and immunofluorescence, Tissue Cell, 8, 125, 1976.
8. Softer, R.L., Angiotensin-converting enzyme and the regulation of vasoactive peptides, Annu. Rev. Biochem., 45, 73, 1976.
9. Erdos, E.G. and Skidgel, R.A., The AI converting enzyme, Lab. Invest., 56, 345, 1987.
10. Cushman, D.W. and Ondetti, M.A., Inhibitors of ACE for treatment of hypertension, Biochem. Pharmacol., 29, 1871, 1980.
11. Johnston, C.I., Jackson, B.J., Larmour, I. et al., Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension, Br. J. Clin. Pharmacol., 18, 2335, 1984.
12. Schwartz, J.B., Taylor, A., Abernathy, D. et al., Pharmacokinetics and pharmacodynamies of enalapril in patients with congestive heart failure and patients with hypertension, J. Cardiovasc. Pharmacol., 7, 767, 1985.
13. Gavras, I. and Gavras, H., The use of ACE inhibitors in hypertension, in ACE Inhibitors, Kostis, J.B. and Felice, E.A., Eds., Alan R. Liss, New York, 1987, 93.
14. Kostis, J.B. and Felice, E.A., Eds., ACE Inhibitors, Alan R. Liss, New York, 1987.
15. Ferguson, R.K. and Vlasses, P.H., Eds., Angiotensin CEI, Futura Publishing, Mount Kisco, NY, 1987.
16. MacGregor, G.A. and Sever, P.S., Eds., Current Advances in ACE Inhibition, Churchill-Livingston, Edinburgh, 1989.
17. Reid, J.L. and Zanchetti, A., ACE Inhibition in the 1990’s, J. Hypertens., 1 (Suppl. 5), S1, 1989.
18. Wood, J.M., The renin-angiotensin system as a therapeutic target, J. Cardiovasc. Pharmacol., 16 (Suppl. 4), S1, 1990.
19. Kaneko, Y. and Laragh, J.H., New developments in ACE inhibitory action, Am. J. Hypertens., 4 (Suppl.), 1S, 1991.
20. Clozel, J.P. and Owens, G.K., The renin angiotensin system and the vascular wall from experimental models to man, Hypertension, 18 (Suppl. II), 2, 1991.
21. Skeggs, L.T., Dorer, F.E., Kahn, J.R., Lintz, K.E., and Levine, M., Experimental renal hypertension: the discovery of the renin-AII system, in Biochemical Regulation of Blood Pressure, Soffer, R.L., Ed., John Wiley & Sons, New York, 1981, 3.
22. Kostis, J.B., DeFelice, E.A., and Pianko, L.J., The renin-angiotensin system, in ACE Inhibitors, Kostis, J.B. and Felice, E.H., Eds., Alan R. Liss, New York, 1987, 1.
23. Ondetti, M.A. and Cushman, D.W., Enzymes of the renin-angiotensin system and their inhibitors, Annu. Rev. Biochem., 31, 283, 1982.
24. Cushman, D.W. and Ondetti, M.A., Inhibitors of angiotensin-converting enzyme, Prog. Med. Chem., 17, 41, 1980.
25. Skidgel, R.A., Engelbrecht, S., Johnson, A.R., and Erdos, E.G., Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptides, Peptides, 5, 769, 1984.
26. 2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone, Proc. Natl. Acad. Sci. U.S.A., 82, 1025, 1985.
27. Strittmatter, S.M., Thiele, E.A., Kapiloff, M.S., and Synder, S.H., A rat brain isoenzyme of angiotensin-converting enzyme: unique specificity for amidated peptide substrates, J. Biol. Chem., 260, 9825, 1985.
28. Skidgel, R.A. and Erdos, E.A., The broad substrate specificity of human AI converting enzyme, Clin. Exp. Hypertens., A9 (2 & 3), 243, 1987.
29. Erdos, E.G., The AI converting enzyme, Fed. Proc., 36, 1760, 1977.
30. Skeggs, L., Marsh, W., Kahn, J., and Shumwag, N., The existence of two forms of hypertension, J. Exp. Med., 99, 275, 1954.
31. Ferreira, S.H., A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, Br. J. Pharmacol., 24, 163, 1965.
32. Bakhle, Y.S., Conversion of AI to All by cell-free extracts of dog lung, Nature, 220, 929, 1968.
33. Ferreira, S.H., Bartelt, D.C., and Greene, L.J., Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom, Biochemistry, 9, 2583, 1970.
34. Bunning, P., Holmquist, B., and Riordan, J.F., Functional residues at the active site of ACE, Biochem. Biophys. Res. Commun., 83, 1442, 1978.
35. Erdos, E.G. and Yang, H.Y.T., An enzyme in microsomal fraction of kidney that inactivates bradykinin, Life Sci., 6, 569, 1967.
36. Erdos, E.G. and Yang, H.Y.T., Inactivation and potentiation of the effects of bradykinin, in Hypotensive Peptides, Erdos, E.G., Back, N., and Sicuteri, F., Eds., Springer-Verlag, New York, 1966, 235.
37. Johnston, C.I. and Kohzuki, M., ACE: localization and inhibition, in Current Advances in ACE Inhibition, MacGregor, G.A. and Sever, P.S., Eds., Churchill-Livingston, Edinburgh, 1989, 3.
38. Kokubu, T. and Takada, Y., Biochemistry of human converting enzyme, Clin. Exp. Theory Pract., A9 (2 & 3), 217, 1987.
39. Roth, M., Weitzman, A.F., and Piquilloud, Y., Converting enzyme content of different tissues of the rat, Experientia, 25, 1247, 1969.
40. Cushman, D.W. and Cheung, H.S., Concentration of angiotensin-converting enzyme in tissues of the rat, Biochim. Biophys. Acta, 250, 261, 1971.
41. Miyazaki, M., Okunishi, H., Mishimura, K., and Toda, N., Vascular angiotensinconverting enzyme activity in man and other species, Clin. Sci., 66, 39, 1984.
42. 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat, J. Hypertens., 4, 759, 1986.
43. 3H-captopril: tissue localization and changes in different models of hypertension in the rat, J. Clin. Invest., 80, 841, 1987.
44. Okunishi, H., Miyazaki, M., Okamura, T., and Toda, N., Different distribution of two types of All-generating enzymes in the aortic wall, Biochem. Biophys. Res. Commun., 149, 1186, 1987.
45. Velletri, P. and Bean, B.L., The effect of captopril on rat aortic angiotensin-converting enzyme, J. Cardiovasc. Pharmacol., 4, 315, 1982.
46. Saye, J.A., Singer, H.A., and Peach, M.J., Role of endothelium in conversion of AI to All in rabbit aorta, Hypertension, 6, 216, 1984.
47. 3H) captopril: localization to a striatonigral pathway, Proc. Natl. Acad. Sci. U.S.A., 81, 1599, 1984.
48. 124I-351A, a specific enzyme inhibitor, Brain Res., 347, 192, 1985.
49. Chai, S.Y., Mendelsohn, F.A.O., and Paxinos, G., Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography, Neuroscience, 2, 615, 1987.
50. Yang, H.Y.T. and Neff, N.H., Distribution and properties of ACE of rat brain, J. Neurochem., 19, 2243, 1972.
51. Schelling, P., Ganten, U., Sponer, G., Unger, T., and Ganten, D., Components of the renin-angiotensin system in the cerebrospinal fluid of rats and dogs with special consideration of the origin and the fate of angiotensin II, Neuroendocrinology, 31, 297, 1980.
52. Rix, E., Ganten, D., Schull, B., Unger, T., and Taugner, R., Converting enzyme in the chorioid plexus, brain and kidney: immunocytochemical and biochemical studies in rats, Neurosci. Lett., 22, 125, 1981.
53. Paul, M., Printz, M.P., Harms, E., Unger, T., Lang, R.E., and Ganten, D., Localization of renin (ED 3.4.23) and converting enzyme (EC 3.4.15.1) in nerve endings of rat brain, Brain Res., 334, 315, 1985.
54. Unger, T. and Gohlke, P., Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of CEI, Am. J. Cardiol., 65 (19), 31, 1990.
55. Koshiya, K., Okada, M., Imai, K., Kato, I., Tanka, R., Hatanaka, H., and Kato, T., Localization of angiotensin-converting enzyme, prolylendopeptidase and other peptidase in cultured neuronal or glial cells, Neurochem. Int., 7, 125, 1985.
56. Clemens, D.L., Okamura, T., and Inagami, T., Subcellular localization of angiotensinconverting enzyme in cultured neuroblastoma cells, J. Neurochem., 47, 1837, 1986.
57. Johnston, C.L, Fabris, B., Yamada, H., Mendelsohn, F.A.O. et al., Comparative studies of tissue inhibition by ACE inhibitors, J. Hypertens., 7 (Suppl. 5), S11, 1989.
58. Yamada, H., Fabris, B., Allen, A.M., Jackson, B., Johnston, C.I., and Mendelsohn, F. A.O., Localization of ACE in rat heart, Circ. Res., 1989.
59. Erdos, E.G., Schulz, W.W., Gafford, J.T., and Defendini, R., Neutral metalloen-dopeptidase in human male genital tract. Comparison to angiotensin I-converting enzyme, Lab. Invest., 52, 437, 1985.
60. Yasui, T., Alhenc-Gelas, F., Corvol, P., and Menard, J., Angiotensin I-converting enzyme in amniotic fluid, J. Lab. Clin. Med., 104, 741, 1984.
61. Ganten, D., Printz, M., Phillips, M.I., and Scholkens, B.A., Eds., The Renin Angiotensin System in the Brain, Springer-Verlag, Heidelberg, 1982.
62. Sen, G.C., Thekkamkara, T.J., and Kumar, R.S., ACE: structural relationship of the testicular and pulmonary forms, J. Cardiovasc. Pharmacol., 16 (Suppl. 4), 3, 1990.
63. El-Dorry, H., Bull, H.G., Iwata, K., Thornberry, N.A., Cordes, E.H., and Soffer, R.L., Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase, J. Biol. Chem., 257, 14128, 1982.
64. El-Dorry, H., Pickett, C.B., MacGregor, J.S., and Soffer, R.L., Tissue-specific expression of mRNAs for dipeptidyl carboxypeptidase isozymes, Proc. Natl. Acad. Sci. U. S.A., 79, 4295, 1982.
65. Soubrier, F., Alhenc-Gelas, F., Hubert, C. et al., Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning, Proc. Natl. Acad. Sci. U.S.A., 85, 9386, 1988.
66. Bernstein, K.E., Martin, B.M., Bernstein, E.A., Linton, J., Striker, L., and Striker, G., The isolation of angiotensin-converting enzyme cDNA, J. Biol. Chem., 263(23), 11021, 1988.
67. Roy, S.N., Kusari, J., Soffer, R.L., Lai, C.Y., and Sen, G.C., Isolation of cDNA clones of rabbit ACE: identification of two distinct mRNAs for the pulmonary and the testicular isozymes, Biochem. Biophys. Res. Commun., 155, 678, 1988.
68. Kumar, R.S., Kusari, J., Roy, S.N., Soffer, R.L., and Sen, G.C., Structure of testicular ACE: a segmental mosaic isozyme, J. Biol. Chem., 264, 16754, 1989.
69. Lattion, A.L., Soubrier, F., Allegrini, J., Hubert, C., Corvol, P., and Alhenc-Gelas, F., The testicular transcript of the Al-converting enzyme encodes for the ancestral, non-duplicated form of the enzyme, F LBS Lett., 252, 99, 1989.
70. Ehlers, M.R.W., Fox, E.A., Strydom, D.A., and Riordan, J.F., Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme, Proc. Natl. Acad. Sci. U.S.A., 86, 7741, 1989.
71. Huggins, C.G. and Thampi, N.S., A simple method for determination of angiotensin I converting enzyme, Life Sci., 7, 633, 1968.
72. Lee, H.J., Larue, J.N., and Wilson, I.B., Angiotensin-converting enzyme from porcine plasma, Biochim. Biophys. Acta, 235, 521, 1971.
73. Piquilloud, Y., Reinharz, A., and Roth, M., Studies on angiotensin converting enzyme with different substrates, Biochim. Biophys. Acta, 206, 136, 1970.
74. Cheung, H.S. and Cushman, D.W., Inhibition of homogenous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops Tararaed, Biochim. Biophys. Acta, 293, 451, 1973.
75. Dorer, F.E., Kahn, J.R., Lentz, K.E., and Skeggs, L.T., Purification and properties of angiotensin-converting enzyme from hog lung, Circ. Res., 31, 356, 1972.
76. Oparil, S., Koemer, T., and O’Donoghue, J.K., Structural requirements for substrates and inhibitors of angiotensin I converting enzyme in vivo and in vitro, Circ. Res., 34, 19, 1973.
77. King, S.J., Booyse, F.M., Lin, P.H., Traylor, M., Markates, A.J., and Oparil, S., Hypoxia stimulates endothelial cell angiotensin converting enzyme antigen synthesis. Am. J. Physiol. (256) Cell Physiol., 25, C1231, 1989.
78. Cushman, D.W. and Cheung, H.S., Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung, Biochem. Pharmacol., 20, 1637, 1971.
79. DelVecchio, P.J. and Smith, J.R., Synthesis of angiotensin converting enzyme by endothelial cells in culture in vivo, J. Cell Physiol., 108, 308, 1981.
80. Krulewitz, A.H. and Fanburg, B.L., Stimulation of bovine endothelial cell angiotensin I converting enzyme activity by cyclic AMP-related agents, J. Cell Physiol., 129, 147, 1986.
81. Jackson, R.M., Narkates, A.J., and Oparil, S., Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia, J. Appl. Physiol., 60, 1121, 1986.
82. Keane, P.M., Kay, J.J., Suyama, K.L., Gauthier, D., and Andrew, K., Lung angiotensin converting enzyme activity in rats with pulmonary hypertension, Thorax, 37, 198, 1982.
83. Krulewitz, A.H. and Fanburg, B.L., The effect of oxygen tension on the in vitro production and release of angiotensin converting enzyme by bovine pulmonary artery endothelial cells, Am. Rev. Respir. Dis., 130, 866, 1984.
84. Forstuma, T., Tikkanen, L, Gronhagen-Riska, C., and Fyhrquist, F., Dissociation of the effect of captopril on blood pressure and angiotensin converting enzyme in serum and lungs of spontaneously hypertensive rats, Acta Pharmacol. Toxicol., 49, 416, 1981.
85. Fyhrquist, F., Gronhagen-Riska, C., Hortling, L., Forslund, T., Tikkanen, L, and Klockars, M., The induction of angiotensin converting enzyme by its inhibitors, Clin. Exp. Hypertens., A5, 1319, 1983.
86. King, S.J., Oparil, S., and Berecek, K.H., Neuronal angiotensin converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI), Mol. Cell. Neurosci., 2, 13, 1991.
87. Schunkert, H., Hirsch, A.T., Pinto, Y., Pelletier, P., Jacob, H., Remme, W.J., Ingelfinger, J.R., and Dzau, V.J., Feedback regulation of angiotensin converting enzyme mRNA and activity by angiotensin II, Circulation, 82, 230, 1990.
88. Ferreira, S.H., A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca, Br. J. Pharmacol., 24, 163, 1965.
89. Ferreira, S.H., Bartelt, D.C., and Greene, L.J., Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom, Biochemistry, 9, 2583, 1970.
90. Ondetti, M.A., Williams, N.J., Sabo, E.F., Pluscec, J., Weaver, E.R., and Kocy, O., Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis, Biochemistry, 10, 4033, 1971.
91. Engel, S.L., Schaeffer, T.R., Gold, B.I., and Rubin, B., Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bradykinin by synthetic peptides, Proc. Soc. Exp. Biol. Med., 140, 240, 1972.
92. Greene, L.J., Camargo, A.C.M., Krieger, E.M., Stewart, J.M., and Ferreira, S.H., Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom, Circ. Res., 30, 1162, 1972.
93. Engel, S.L., Schaeffer, T.R., Waugh, M.H., and Rubin, B., Effects of the nonapeptide SQ 20,881 on blood pressure of rats with experimental renovascular hypertension, Proc. Soc. Exp. Biol. Med., 143, 483, 1973.
94. Muirhead, E.E., Brooks, B., and Arora, K.K., Prevention of malignant hypertension by the synthetic peptide SQ 20,881, Lab. Invest., 30, 129, 1974.
95. Gavras, H., Brunner, H.R., Laragh, J.H., Sealey, J.E., Gavras, I., and Vukovich, R. A., An ACE inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N. Engl. J. Med., 291, 817, 1974.
96. Samuels, A.I., Miller, E.D., Jr., Fray, J.C.S., Haber, E., and Barger, A.C., Renin-angiotensin antagonists and the regulation of blood pressure, Fed. Proc., 35, 2512, 1976.
97. Case, D.B., Wallace, J.M., Keim, H.J. et al., Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme, N. Engl. J. Med., 296, 641, 1977.
98. Miller, E.D., Samuels, A.I., Haber, E., and Barger, A.C., Inhibition of angiotensin conversion in experimental renovascular hypertension, Science, 111, 1108, 1972.
99. Ayers, R.C., Vaughan, E.D., Yancey, M.R. et al., Effect of 1-sarcosin-8-alanine All and converting enzyme inhibitor on renin release in dog acute renovascular hypertension, Circ. Res., 34 - 35 (1), 27, 1974.
100. Gavras, H., Liang, C.S., and Brunner, H.R., Redistribution of regional blood flow after inhibition of the angiotensin-converting enzyme, Circ. Res., 43 (Suppl. 1), 1, 1978.
101. Hollenberg, N.K., Swartz, S.L., Passan, D.R., and Williams, G.H., Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension, N. Engl. J. Med., 301, 9, 1979.
102. Johnson, J.G., Black, W.D., Vukovich, R.A., Hatch, F.E., Jr., Friedman, B.I., Blackwell, C.F., Shenouda, A.W., Share, L., Shade, R.E., Acchiardo, S.R., and Muirhead, E.E., Treatment of patients with severe hypertension by inhibition of angiotensin-converting enzyme, Clin. Sci. Mol. Med., 48, 53S, 1975.
103. Tiffl, C.P., Gavras, H., Kershaw, G.R., Gavras, I., Brunner, H.R., Liang, C.S., and Chobanian, A.V., Converting enzyme inhibition in hypertensive emergencies, Ann. Intern. Med., 90, 1, 1979.
104. Gavras, H., Faxon, D.P., Berkoben, J. et al., Angiotensin-converting enzyme inhibition in patients with congestive heart failure, Circulation, 58, 770, 1978.
105. Curtiss, C., Cohn, J.N., Vrobel, T., and Franciosa, J.A., Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure, Circulation, 58, 763, 1978.
106. Gavras, H., Andrews, P., and Papadakis, N., Reversal of experimental delayed cerebral vasospasm by angiotensin-converting enzyme inhibition, J. Neurosurg., 55, 6, 1981.
107. Ondetti, M.A., Rubin, B., and Cushman, D.W., Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents, Science, 196, 441, 1977.
108. Cushman, D.W., Cheung, H.S., Sabo, E.F., and Ondetti, M.A., Design of potent competitive inhibitors of angiotensin-converting enzyme, Biochemistry, 16, 5484, 1977.
109. Patchett, A.A., Harris, E., Tristram, E.W. et al., A new class of angiotensin-converting enzyme inhibitors, Nature, 228, 280, 1980.
110. Antonaccio, M. and Cushman, D., Drugs inhibiting the renin-angiotensin system, Fed. Proc., 40, 2275, 1981.
111. Migdalof, B.H. et al., Evidence for dynamic interconversion of captopril and its disulfide metabolites in vivo, Fed. Proc., 39, 757, 1980.
112. Case, D.B., Atlas, S.A., Laragh, J.H., Sealey, J.E., Sullivan, P.A., and McKinstry, D.N., Clinical experience with blockade of the renin-angiotensin-aldosterone system with an oral converting enzyme inhibitor (SQ 14,225; captopril) in hypertensive patients, Prog. Cardiovasc. Dis., 21, 195, 1978.
113. Jenkins, A.C. and McKinstry, D.N., Review of clinical studies of hypertensive patients treated with captopril, Med. J. Aust. (Spec. Suppl.), 32, 1979.
114. Gavras, H., Brunner, H.R., Turini, G.A., Kershaw, G.R., Tifft, C.P., Cuttelod, S., Gavras, I., Vukovich, R.A., and McKinstry, D.N., Antihypertensive effect of the oral ACE inhibitor SQ 14,225 in man, N. Engl. J. Med., 298, 991, 1978.
115. Bauer, J.H., ACE inhibitors, Am. J. Hypertens., 3, 331, 1990.
116. Duchin, K.L., Singhvi, S.M., Willard, D.A., Migdalo, F.E.B.H., and McKinstry, D.N., Captopril kinetics, Clin. Pharmacol. Ther., 31, 452, 1982.
117. Todd, P.A. and Hell, R.C., Enalapril. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure, Drugs. 31, 198, 1986.
118. Frohlich, E.D., ACE inhibitor: present and future, Hypertension, 13, 1125, 1989.
119. Vlasses, P.H., Larijani, G.E., Conner, D.P. et al. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor, Clin. Pharmacol., 4, 27, 1985.
120. Sweet, C.S., Pharmacological properties of the converting enzyme inhibitor, enalapril maléate (MK-421), Fed. Proc., 42, 167, 1983.
121. Petrillo, E.W. and Ondetti, M.A., Angiotensin-converting enzyme inhibitor: medicinal chemistry and biological actions, Med. Res. Rev., 2, 1, 1982.
122. Ondetti, M.A. and Cushman, D.W., Angiotensin-converting enzyme inhibitor: biochemical properties and biological action, Crit. Rev. Biochem., 16, 381, 1984.
123. Wyvratt, M.J. and Patchett, A.A., Recent developments in the design of angiotensinconverting enzyme inhibitor, Med. Res. Rev., 5, 483, 1985.
124. Kostis, J., Raía, J.J., Jr., DeFelice, E.A., Barone, J.A., and Letter, R.G., Comparative clinical pharmacology of ACE inhibitors, in Angiotensin Converting Enzyme Inhibitors, Kostis, J.B. and DeFelice, E.A., Eds., Alan R. Liss, New York, 1987, 19.
125. DeFelice, E.A. and Kostis, J.B., New ACE inhibitors, in Angiotensin Converting Enzyme Inhibitors, Kostis, J.B. and DeFelice, E.A., Eds., Alan R. Liss, New York, 1987, 213.
126. Cushman, D.W., Ondetti, M.A., Gordon, E.M., Natarajean, S., Karanewsky, D.S., Krapcho, J., and Petrillo, E.W., Jr., Rational design and biochemical utility of specific inhibitors of ACE, J. Cardiovasc. Pharmacol., 10 (Suppl. 7), S17, 1987.
127. Gravras, H., Brunner, H.R., Laragh, J.H., Sealey, J.E., Garvas, I., and Vukovich, R. A., An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients, N. Engl. J. Med., 291, 817, 1974.
128. Jenkins, A.C., Dreslinski, G.R., Tadors, S.S., Groel, J.T., Fand, R., and Herczeg, S. A., Captopril in hypertension; seven years later, J. Cardiovasc. Pharmacol., 1 (Suppl. 1), S96, 1985.
129. Messerli, F.H., Orens, S., and Grossman, E., Left ventricular hypertrophy and antihypertensive therapy, Drugs, 35 (Suppl. 5), 27, 1988.
130. Sullivan, P.A., Kellerher, M., Twomey, M., and Dineen, M., Effects of converting enzyme inhibitor on blood pressure, plasma-renin activity and plasma-aldosterone in hypertensive diabetics compared to patients with essential hypertension, J. Hypertens., 3, 359, 1985.
131. Zannad, F., The emerging role of ACE inhibitors in the treatment of cardiovascular disease, J. Cardiovasc. Pharmacol., 15 (Suppl. 2), S1, 1990.
132. Swartz, S.L. and Williams, G.H., Angiotensin-converting enzyme inhibition and prostaglandins, Am. J. Cardiol., 29 (6), 1405, 1982.
133. Cushman, D.W., Wang, F.L., Fung, W.C. et al., Comparison in vitro, ex vitro and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE), Br. J. Clin. Pharmacol., 28, 115S, 1989.
134. Cohen, M.L., Kurz, K.D., and Schenck, K.W., Tissue angiotensin-converting enzyme inhibition as an index of the disposition of enalapril (MK-421) and metabolite MK-422, J. Pharmacol. Exp. Ther., 226 (1), 192, 1983.
135. Unger, T.H., Ganten, D., and Lang, R.E., Pharmacology of CEI: new aspect, Clin. Exp. Hypertens. A, 5 (7/8), 1333, 1983.
136. Waeber, B., Nussberger, J., and Brunner, H.R., Angiotensin-converting inhibitors in hypertension, in Hypertension: Pathophysiology, Diagnosis, and Management, Larage, J.H. and Brenner, B.M., Eds., Raven Press, New York, 1990, chap. 140.
137. De Silva, P.E., Husain, A., Smeby, R.R., and Khairallah, P.A., Measurement of immunoreactive angiotensin peptides in rat tissues: some pitfalls in angiotensin II analysis, Anal. Biochem., 174, 80, 1988.
138. Nussberger, J., Brunner, D.B., Waeber, B., and Brunner, H.R., True versus immunoreactive angiotensin II in human plasma, Hypertension, 7 (Suppl. I), 1, 1985.
139. Nussberger, J., Brunner, D.B., Waeber, B., and Brunner, H.R., Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma, Hypertension, 8, 476, 1986.
140. Unger, T., Gohlke, P., Paul, M., and Rettig, R., Tissue renin-angiotensin systems: fact or fiction?, J. Cardiovasc. Pharmacol., 18 (Suppl. 2), S20, 1991.
141. Gavras, H., Brunner, H.R., Turini, G.A., Kershaw, G.R., Fiffi, C.P., Cuttelod, S., Vukovich, R.A., and McKinstry, D.N., Antihypertensive effect of oral angiotensin converting enzyme inhibitor SQ 14225 in man, N. Engl. J. Med., 298, 991, 1978.
142. Case, D.B., Atlas, S.A., Laragh, J.H., Sealey, J.E., Sullivan, P.A., and McKinstry, D.N., Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225 or captopril) in hypertensive patients, Prog. Cardiovasc. Dis., 21, 195, 1978.
143. Vukovich, R.A., McKinstry, D.N., and Gavras, I., Oral angiotensin-converting enzyme inhibitor in long term treatment of hypertensive patients, Ann. Intern. Med., 90, 19, 1979.
144. Case, D.B., Atlas, S.A., Laragh, J.H., Sullivan, P.A., and Sealey, J.E., Use of first dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response, J. Cardiovasc. Pharmacol., 2, 239, 1980.
145. Waeber, B., Gavras, I., Brunner, H.R., Cook, C.A., Charocopos, F., and Gavras, H., Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity, Am. Heart J., 103, 384, 1982.
146. Unger, T. and Gohlke, P., Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am. J. Cardiol., 65, 31, 1990.
147. Fyhrquist, F., Forslund, T., Tikkanen, I., and Gronhagen-Riska, C., Induction of angiotensin I converting enzyme in rat lung with captopril SQ 14285, Eur. J. Pharmacol., 67, 473, 1980.
148. Johnston, C.I., Mendelsohn, F.A.O., Cubela, R.B., Jackson, B., Kihzuki, M., and Fabris, B., Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors, J. Hypertens., 6 (Suppl. 3), S17, 1988.
149. l25I-labelled MK 351 A, J. Hypertens., 2 (Suppl. 3), 41, 1984.
150. Chai, S.Y., Mendelsohn, F.A.O., and Paxinos, G., Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography, Neuroscience, 20, 615, 1987.
151. Fyhrquist, F., Tikkanen, I., Gronhagen-Riska, C., Hurtling, L., and Hichens, M., Inhibitor binding assay for angiotensin converting enzyme, Clin. Chem., 30, 696, 1984.
152. Jackson, B., Cubela, R., and Johnston, C.I., Angiotensin converting enzyme measurement in human serum using radioinhibitor ligand binding, Aust. J. Exp. Biol. Med. Sei., 64, 149, 1986.
153. 125I-MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat, J. Hypertens., 4, 759, 1986.
154. Johnston, C.I., Cubela, R., and Jackson, B., Inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat, Clin. Exp. Pharmacol. Physiol. 15, 123, 1988.
155. Jackson, B., Cubela, R., and Johnston, C.I., Tissue angiotensin converting enzyme (ACE) during changes in the renin-angiotensin system, J. Cardiovasc. Pharmacol., 10 (Suppl. 70), S137, 1987.
156. Campbell, D.J., Circulating and tissue angiotensin systems, J. Clin. Invest., 79, 1, 1987.
157. Dzau, V. J., Vascular renin-angiotensin: a possible autocrine or paracrine system in control of vascular function, J. Cardiovasc. Pharmacol., 6 (Suppl. 3), S377, 1984.
158. Mizuno, K., Nakamura, M., Higashimori, K., and Higashimori, K., Local generation and release of angiotensin II in peripheral vascular tissue, Hypertension, 11, 223, 1988.
159. Mizuno, K., Tani, M., Niimura, S. et al., Direct evidence for local generation and release of angiotensin II in human vascular tissue, Biochem. Biophys. Res. Commun., 165, 457, 1989.
160. Kifor, I. and Dzau, V.J., Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensin, Circ. Res., 60, 422, 1987.
161. Unger, T., Badoer, E., Ganten, D., Lang, R.E., and Rettig, R., Brain angiotensin: pathways and pharmacology, Circulation, 77 (Suppl. I), 40, 1988.
162. Lindpainter, K., Jin, M., Wilhalm, M.J., Suzuki, F., Linz, W., Scholkens, B.A., and Ganten, D., Intracardiac generation of angiotensin and its physiologic role, Circulation, 11 (Suppl. I), 118, 1988.
163. Inagami, L, Ilamura, L, Clemens, D., Celio, M.R., Naruse, K., and Naruse, M., Local generation of angiotensin in the kidney and in tissue culture, Clin. Exp. Hypertens. A, 5, 1137, 1983.
164. Campbell, D.J. and Habener, J.F., Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ, Endocrinology, 121, 16, 1987.
165. Nakamura, M., Inagami, T., Ogihara, T., and Kumahara, Y., Effect of captopril on angiotensin II release from vascular tissues in rats, Clin. Exp. Hypertens., 9 (2-3), 477, 1987.
166. Mizuno, K., Tani, M., Niimura, S., Hashimoto, S., Satoh, A., Shimamoto, K., Inagami, T., and Fukuchi, S., Direct evidence for local generation and release of All in human vascular tissue, Biochem. Biophys. Res. Commun., 165(1), 457, 1989.
167. Higashimori, K., Nakamura, M., Tabuchi, Y., Nagano, M., Mikami, H., Ogihara, T., and Inagami, T., Angiotensin converting enzyme inhibitors suppress the vascular renin angiotensin system of spontaneously hypertensive rats, Am. J. Hypertens., 4, 56S, 1991.
168. Miyazaki, M., Ikunishi, H., Mishimura, K., and Toda, N., Vascular angiotensin converting enzyme activity in man and other species, Clin. Sci., 66, 39, 1984.
169. 3H-captopril. Tissue localization and changes in different models of hypertension in the rat, J. Clin. Invest., 30, 841, 1987.
170. Oliver, J.A. and Sciacca, R.R., Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat, J. Clin. Invest., 14, 1247, 1984.
171. Malik, K.U. and Nasjletti, A., Facilitation of adrenergic transmission by locally generated All in rat mesenteric arteries, Circ. Res., 38, 26, 1976.
172. + transport in vascular smooth muscle cells, J. Cardiovasc. Pharmacol., 11, 136, 1988.
173. Toda, N., Endothelium-dependent relaxation induced by angiotensin II and histamine in isolated arteries of dog, Br. J. Pharmacol., 81, 301, 1984.
174. Heagerty, A.M., All: vasconstrictor or growth factor?, J. Cardiovasc. Pharmacol., 18 (Suppl. 2), S14, 1991.
175. Mulvagh, S.L., Roberts, R., and Schneider, M.D., Cellular oncogenes in cardiovascular disease, J. Mol. Cell. Cardiol., 20, 657, 1988.
176. Rauscher, F.J., III, Sambucetti, L.C., Curran, T., Distel, R.J., and Spiegelman, B.M., A common DNA binding site for fos complexes and transcription factor AP-1, Cell, 52, 471, 1988.
177. Marban, E. and Koretsune, Y., Cell calcium oncogenes and hypertrophy, Hypertension, 15, 652, 1990.
178. Allen, I.S., Cohen, N.M., Dhalian, R.S., Gaa, S.T., Lederer, W.J., and Rogers, T.B., All increases contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into the underlying biochemical mechanisms, Circ. Res., 62, 524, 1988.
179. Griendling, K.K., Berk, B.C., Ganz, P., Gimrone, M.A., and Alexander, R.W., Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. Hypertension, 9 (Suppl. III), 181, 1987.
180. Geisterfer, A.A.T., Peach, M.J., and Owens, G.K., Angiotensin II induces hypertrophy, not hyperplasia of cultured rat aortic smooth muscle cells, Circ. Res., 62, 749, 1988.
181. Berk, B.C., Vekshtein, V., Gordon, H.M., and Tsuda, T., Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells, Hypertension, 13, 305, 1989.
182. Naftilan, A.J., Pratt, R.E., Eldridge, C.S., Lin, H.L., and Dzau, V.J., Angiotensin II induces c-fos expression in smooth muscle via transcriptional control, Hypertension, 13, 706, 1989.
183. Naftilan, A.J., Gilliland, G.K., Eldridge, C.S., and Kraft, A.S., Induction of the protooncogene c-jun by angiotensin II, Mol. Cell. Biol., 10 (10), 5536, 1990.
184. Rainer, R.S., Eldridge, C.S., Gilliland, G.K., and Naftilan, A.J., Antisense oligonucleotide to c-fos blocks the angiotensin II-induced stimulation of protein synthesis in rat aortic smooth muscle cells, Hypertension, 16 (Abstr.), 326, 1990.
185. Itoh, H., Pratt, R.E., and Dzau, V.J., Antisense oligonucleotides complementary to PDGF mRNA attenuate angiotensin II-induced vascular hypertrophy, Hypertension, 16 (Abstr), 325, 1990.
186. + exchange and stimulates growth in cultured vascular smooth muscle cells, J. Hyper tens., 6 (Suppl. 4), S438, 1988.
187. Campbell-Boswell, M., and Robertson, L.A., Jr., Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro, Exp. Mol. Pathol., 35, 265, 1981.
188. Chamley-Campbell, J.H., Campbell, G.R., and Ross, R., Phenotype dependent response of cultured aortic smooth muscle to serum mitogens, J. Cell Biol., 89, 379, 1981.
189. DeMey, J.G.R., Uitendaal, M.P., Boonen, H.C.M., Vrijdag, M.J.J.F., Daemen, M.J.A.P., and Struyker-Boudier, H.A.J., Acute and long-term effects of tissue culture on contractile reactivity in renal arteries of the rat, Circ. Res., 65, 1125, 1989.
190. Komuro, I., Kurabayashi, M., Takaku, F., and Yazaki, Y., Expression of cellular oncogenes in the myocardium during the developmental stage and pressure-overloaded hypertrophy of the rat heart, Circ. Res., 62, 1075, 1988.
191. Offerenshaw, J.D., Heagerty, A.M., West, K.P., and Swales, J.D., The effects of coarctation hypertension upon vascular inositol phospholipid hydrolysis in Wistar rats, J. Hypertens., 6, 733, 1988.
192. Ahmed, S.S., Levinson, G.E., Weisse, A.B., and Regan, T.J., The effect of angiotensin on myocardial contractility, J. Clin. Pharmacol., 15, 276, 1975.
193. Assad, M.M. and Antonaccio, M.J., Vascular wall renin in spontaneously hypertensive rats, Hypertension, 4, 487, 1982.
194. Unger, T., Hubner, D., Schull, B., Lang, R.E., Rascher, W., Retting, R., and Ganten, D., Effect of chronic oral captopril treatment on tissue renin concentration and converting enzyme activity in stroke-prone spontaneously hypertensive rats, in Hypertensive Mechanisms, Rascher, W., Clough, D., and Ganten, D., Eds., Schattauer Verlag, New York, 1982, 768.
195. Cohen, M.L. and Kutz, K.D., Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421, J. Pharmacol. Exp. Ther., 220, 63, 1982.
196. Cohen, M.L., Wiley, K.S., and Kurz, K.D., Effect of acute oral administration of captopril and MK-421 on vascular angiotensin converting enzyme activity in the spontaneously hypertensive rat, Life Sci., 32, 565, 1983.
197. Unger, T., Gohlke, P., Ganten, D., and Lang, R.E., Converting enzyme inhibitors and their effects on the renin-angiotensin system of the blood vessel wall, J. Cardiovasc. Pharmacol., 13 (Suppl. 3), S8, 1989.
198. Berecek, K.H., Okuno, T., Nagahama, T., and Oparil, S., Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat, Hypertension, 6, 689, 1983.
199. Berecek, K.H. and Shier, D.N., Alterations in renal vascular reactivity induced by chronic central administration of captopril in the spontaneously hypertensive rat, Clin. Exp. Hypertens., A8 (7), 1081, 1986.
200. Berecek, K.H., Kirk, K.A., Nagahama, S., and Oparil, S., Alterations in sympathetic function in spontaneously hypertensive rats after chronic administration of captopril, Am. J. Physiol., 252, H796, 1987.
201. Freslon, J.L. and Giudicelli, J.F., Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats, Br. J. Pharmacol., 80 (3), 533, 1983.
202. Christensen, K.L., Jespersen, L.T., and Mulvany, M.J., Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure, J. Hypertens., 1 (2), 83, 1989.
203. Lee, R.M., Berecek, K.H., Tsoporis, J., McKenzie, R., and Triggle, C.R., Prevention of hypertension and vascular changes by captopril treatment, Hypertension, 17 (2), 141, 1991.
204. Ertl, G., Kloner, R.A., Alexander, R.W., and Braunwald, E., Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor, Circulation, 65, 40, 1982.
205. Linz, W., Scholkens, B.A., and Han, Y.F., Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts, J. Cardiovasc. Pharmacol., 8 (Suppl. 10), S91, 1986.
206. Scholkens, B.A., Linz, W., and Martorana, P.A., Experimental cardiovascular benefits of angiotensin converting enzyme inhibitors: beyond blood pressure reduction, J. Cardiovasc. Pharmacol., 18 (Suppl. 2), S26, 1991.
207. Martorana, P.A., Kettenbach, B., Breipohl, G., Linz, W., and Scholkens, B.A., Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist, Eur. J. Pharmacol., 182, 395, 1990.
208. Scholkens, B.A. and Linz, W., Cardioprotective effects of angiotensin converting enzyme inhibitors: experimental proof and clinical perspectives, Clin. Physiol. Biochem., 8 (Suppl. 1), 33, 1990.
209. Ganten, D., Hermann, K., Bayer, C., Unger, T., and Lang, R.E., Angiotensin synthesis in the brain and increased turnover in hypertensive rats, Science, 221, 869, 1983.
210. Ganten, D., Fuxe, K., Phillips, M.L, Mann, J.F.E., and Ganten, U., The brain isorenin-angiotensin system: biochemistry, localization and possible role in drinking and blood pressure regulation, in Frontiers in Neuroendocrinology, Vol. 5, Raven Press, New York, 1978, 61.
211. Phillips, M.L and Kimura, B., Converting enzyme inhibitors and brain angiotensin, J. Cardiovasc. Pharmacol., 8 (Suppl. 10), S82, 1986.
212. Lind, R.W., Swanson, L.W., and Ganten, D., Organization of angiotensin II immu-noreactive cells and fibers in the rat nervous system, Neuroendocrinology, 40, 2, 1985.
213. Campbell, D.J., Bouhnik, J., Menard, J., and Corvol, P., Identity of angiotensinogen precursors of rat brain and liver, Nature, 308, 208, 1984.
214. Mendelsohn, F.A.O., Quirion, R., Saavedra, J.M., Aguilera, G., and Catt, K.J., Autoradiographic localization of angiotensin II receptors in rat brain, Proc. Natl. Acad. Sci. U.S.A., 81, 1575, 1984.
215. Fishman, M., Zimmerman, E., and Slater, E., Renin and angiotensin: the complete system within the neuroblastoma X glial cell, Science, 214, 921, 1981.
216. Hermann, K., Raizada, M.K., Sumners, C., and Phillips, M.I., Immunocytochemical and biochemical characterization of angiotensin I and II in cultured neuronal and glial cells from rat brain, Neuroendocrinology, 47, 125, 1988.
217. Hermann, K., Phillips, M.I., Hilgenfeldt, U., and Raizada, M.K., Biosynthesis of angiotensinogen and angiotensins by brain cells in primary culture, J. Neurochem., 51, 398, 1988.
218. Peach, M. J., Renin-angiotensin system: biochemistry and mechanisms of action, Physiol-Rev., 57, 313, 1977.
219. Vallotton, M.B., The renin-angiotensin system, Trends Pharmacol. Sci., 8, 69, 1987.
220. Epstein, A.N., Fitzsimons, J.T., and Rolls, B.J., Drinking induced by injection of angiotensin into the brain of the rat, J. Physiol. (London), 210, 457, 1970.
221. Bradford, H.F., Chemical Neurobiology, W.H. Freeman, New York, 1986, 265.
222. Felix, D. and Schelling, P., Angiotensin converting enzyme blockade by captopril changes antiotensin II receptors and angiotensinogen concentrations in the brain of SHR-SP and WKY rats, Neurosci. Lett., 34, 45, 1982.
223. Sladek, C.D. and Armstrong, W.E., Effect of neurotransmitters and neuropeptides on vasopressin release, in Vasopressin: Principles and Properties, Gash, D.M. and Boer, G.J., Eds., Plenum Press, New York, 1987, 275.
224. Schomig, A., Dietz, R., Rascher, W., Luth, J.B. et al., Sympathetic vascular tone in spontaneously hypertensive rats, Klin. Wochenschr., 56 (Suppl. I), 131, 1978.
225. Crofton, J.T., Share, L., Shade, R.E., Allen, C., and Tarnowski, D., Vasopressin in the rat with spontaneous hypertension, Am. J. Physiol., 235 (4), H361, 1978.
226. Dietz, R., Schomig, A., Haebara, H., Mann, J.F. et al., Studies on the pathogenesis of spontaneous hypertension of rats, Circ. Res., 43 (Suppl. I), 98, 1978.
227. Plunkett, L.M. and Saavedra, J.M., Increased angiotensin II binding affinity in the nucleus tractus solitarius of spontaneously hypertensive rats, Proc. Natl. Acad. Sci. U.S.A., 82, 7721, 1985.
228. Saavedra, J.M., Correa, F.M.A., Kurihara, M., and Shigematsu, K., Increased number of angiotensin II receptors in the subfornical organ of spontaneously hypertensive rats, J. Hypertens., 4 (Suppl. 5), S27, 1986.
229. Castro, R. and Phillips, M.I., Neuropeptide action in nucleus tractus solitarius: angiotensin specificity and hypertensive rats, Am. J. Physiol., 249, R341, 1985.
230. Schelling, P. and Felix, D., Influence of captopril treatment on angiotensin II receptors and angiotensinogen in the brain of spontaneously hypertensive rats, Hypertension, 5, 935, 1983.
231. Hutchinson, J.S., Mendelsohn, F.A.O., and Doyle, A.E., Blood pressure responses of conscious normotensive and spontaneously hypertensive rats to intracerebroventricular and peripheral administration of captopril, Hypertension, 2, 546, 1980.
232. Okuno, T., Nagahama, S., Lindheimer, M.D., and Oparil, S., Attenuation of the development of spontaneous hypertension in rats of chronic central administration of captopril, Hypertension, 5, 653, 1983.
233. Unger, T., Kaufmann-Buhler, I., Scholkens, B., and Ganten, D., Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats, Eur. J. Pharmacol., 70, 467, 1981.
234. Suzuki, H., Kondo, K., Hand, M., and Saruta, T., Role of the brain isorenin-angiotensin system in experimental hypertension in rats, Clin. Sci., 61, 175, 1981.
235. Pochiero, M., Nicoletta, P., Losi, E., Bianchi, A., and Caputi, A.P., Cardiovascular responses of conscious DOCA-salt hypertensive rats to acute intracerebroventricular and intravenous administration of captopril, Pharmacol. Res. Commun., 15, 173, 1983.
236. Heald, A.F. and Ita, C.E., Distribution in rats of an inhibitor of angiotensin-converting enzyme, SQ 14225, as studied by whole body autoradiography and liquid scintillation counting, Pharmacologist, 19, 129, 1977.
237. Vollmer, R.R. and Boccagno, J.A., Central cardiovascular effects of SQ 14225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats, Eur. J. Pharmacol., 45, 117, 1977.
238. Cohen, M.L. and Kurz, K., Angiotensin converting enzyme inhibition in tissue from spontaneously hypertensive rats after treatment with captopril or MK 421, J. Pharmacol. Exp. Ther., 220, 63, 1982.
239. Unger, T., Ganten, D., Lang, R.E., and Scholkens, B.A., Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with two different compounds Hoe 498 and MK 421 in spontaneously hypertensive rats, J. Cardiovasc. Pharmacol., 6, 872, 1984.
240. Unger, T., Schull, B., Rascher, W., Lang, R.E., and Ganten, D., Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat, Biochem. Pharmacol., 19, 3063, 1982.
241. Cohen, M.L. and Kurz, K., Captopril and MK 421; stability on storage, distribution to the central nervous system, and onset of activity, Fed. Proc., 42, 171, 1983.
242. Geppetti, P., Spillantini, M.G., Frilli, S., Petrini, U., Fanciullaci, M., and Sicuteri, F., Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid, J. Hypertens., 5, 151, 1987.
243. Nishimura, K., Alhenc-Gelas, F., White, A., and Erdos, E.G., Activation of membrane-bound kallikrein and renin in the kidney, Proc. Natl. Acad. Sei. U.S.A., 77, 4975, 1980.
244. Swartz, S.L., Williams, G.H., Hollenberg, N.K., Levine, L., Dluhy, R.G., and Moore, T.J., Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man, J. Clin. Invest., 65, 1257, 1980.
245. Crantz, F.R., Swartz, S.L., Hollenberg, N.K., Moore, T.J., Dluhy, R.G., and Williams, G.H., Differences in response to the peptidyldipeptidase hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension, Hypertension, 2, 604, 1980.
246. Ogihara, T., Maruyama, A., Hata, T., Mikami, H., Nakamura, M., Naka, T., Ohde, H., and Kumahara, Y., Hormonal responses to long-term converting enzyme inhibition in hypertensive patients, Clin. Pharmacol. Ther., 30, 328, 1981.
247. Johnston, C.I., Clappison, B.H., Anderson, W.P., and Yasujima, M., Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels, Am. J. Cardiol., 49, 1401, 1982.
248. Sancho, J., Re, R.N., Burton, J., Barger, C.A., and Haber, E., Role of the renin angiotensin system in cardiovascular homeostasis in normal human subjects, Circulation, 53, 400, 1976.
249. Carretero, O.A., Miyazaki, S., and Sdcli, A.G., Role of kinin in the acute antihypertensive effect of the converting enzyme inhibitor, captopril, Hypertension, 2, 18, 1981.
250. Beneto, A., Gavras, H., Stewart, J.M., Vavrek, R.J., Hatinoglou, S., and Gavras, L, Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist, Hypertension, 8, 971, 1986.
251. Scholkens, B.A. and Linz, W., ACE inhibition in mechanisms of “cardioprotection” in acute myocardial ischemia, Klin. Wochenschr., 69 (24), 1, 1991.
252. Dietz, G.J., Rett, K., Jauch, K.W., Wicklmayr, M., Fink, E., Har Guenther, B., Fritz, H., and Mehnert, H., Captopril bei Hyperton mit diabetes mellitus type II, Hen, 12 (I), 16, 1987.
253. Ram well, P.W., Leovey, E.M., and Sintetos, A.L., Regulation of the arachidonic cascade, Biol. Reprod., 16, 70, 1977.
254. Lonigro, A.J., Itskovitz, H.D., Crowshaw, K., and McGiff, J.C., Dependency of renal blood flow on prostaglandin synthesis in the dog, Circ. Res., 32, 712, 1973.
255. Moore, T.J., Crantz, F.R., Hollenberg, N.K., Koletsky, R.J., Leboff, M.S., Swartz, S.L., Levine, L., Podolsky, S., Dluhy, R.G., and Williams, G.H., Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension, Hypertension, 3, 168, 1981.
256. McGiff, J.C., Terragno, N.A., Malik, K.U., and Lonigro, A.J., Release of prostaglandin E-like substance from canine kidney by bradykinin, Circ. Res., 31, 36, 1972.
257. Needelman, P., Wyche, A., Bronson, S.D., Holmberg, M., and Morrison, A.R., Specific regulation of peptide-induced renal prostaglandin biosynthesis, J. Biol. Chem., 254, 9772, 1979.
258. Swartz, S.L., The role of prostaglandins in mediating the effects of angiotensin converting enzyme inhibitors and other antihypertensive drugs, Cardiovasc. Drugs Ther., 1 (1), 39, 1987.
259. Brunner, H.R., Gavras, H., Waeber, B., Kershaw, G.R., Turini, G.A., Vukovich, R.A., McKinstry, D.N., and Gavras, L, Oral angiotensin-converting enzyme inhibitor in long term treatment of hypertensive patients, Ann. Intern. Med., 90, 19, 1979.
260. Case, D.B., Atlas, S.A., Laragh, J.H., Sullivan, P.A., and Sealey, J.E., Use of first dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response, J. Cardiovasc. Pharmacol., 2, 339, 1980.
261. Atlas, S.A., Case, D.B., Sealey, J.E., Laragh, J.H., and McKinstry, D.N., Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis, Hypertension, 1, 274, 1979.
262. Sanchez, R.A., Marco, E., Gilbert, H.B., Raffaele, G.P., Brito, M., Gimenez, M., and Moledo, L.I., Natriuretic effect and changes in renal hemodynamics induced by enalapril in essential hypertension, Drugs, 30 (I), 49, 1985.
263. De Zeeuw, D., Navis, G.J., Donker, A.J.M., and De Jong, P.E., The angiotensin converting enzyme inhibitor enalapril and its effects on renal function, J. Hypertens., 1(1), 93, 1983.
264. Biollaz, J., Brunner, H.R., Gavras, L, Waeber, B., and Gavras, H., Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade, J. Cardiovasc. Pharmacol., 4, 966, 1982.
265. Brunner, H.R., Waeber, B., Nussberger, J., Schailer, M.D., and Gomez, J.H., Long-term clinical experience with enalapril in essential hypertension, J. Hypertens., 1 (1), 103, 1983.
266. Thibonnier, M., Aldigier, J.C., Soto, M.E., Sassano, P., Menard, J., and Corvol, P., Abnormalities and drug-induced alterations of vasopressin in human hypertension, Clin. Sci., 61, 149, 1981.
267. Santucci, A., Luparini, R.L., Ferri, C., Ficara, C., Giarrizzo, C., and Balsano, F., Relationship between vasopressin and the renin-angiotensin aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin, J. Hypertens., 3 (2), 133, 1985.
268. Berecek, K.H., Wyss, J.M., and Swords, B.H., Alterations in vasopressin mechanisms in captopril treated spontaneously hypertensive rats, Clin. Exp. Hypertens. A, 13(5), 1019, 1991.
269. Ammann, F.W., Bolli, P., Kiowski, W., and Buhler, F.R., Enhanced oc-adrenoceptor mediated vasoconstriction in essential hypertension, Hypertension, 3 (I), 119, 1981.
270. Goldstein, D.S., Plasma catecholamines and essential hypertension. An analytical review, Hypertension, 5, 86, 1983.
271. Dietz, R., Schomig, A., Haebara, H., Mann, J.F., Rascher, W., Luth, J.B., Grun-herz, N., and Gross, F., Circ. Res., 43 (I), 98, 1978.
272. Judy, W.V., Wantanabe, A.M., Henry, D.P., Besch, H.R., Jr., Murphy, W.R., and Hockel, H., Circ. Res., 38 (II), 21, 1976.
273. Bickerton, R.K. and Buckley, J.P., Evidence for a central mechanism in angiotensin induced hypertension, Proc. Soc. Exp. Biol. Med., 106, 834, 1961.
274. Simpson, J.B., The circumventricular organs and the central action of angiotensin, Neuroendocrinology, 32, 248, 1981.
275. Khairailah, D.A., Action of angiotensin in adrenergic nerve endings: inhibition of norepinephrine uptake, Fed. Proc., 31, 1351, 1972.
276. Zimmerman, B.G., Actions of angiotensin on adrenergic nerve endings, Fed. Proc., 37, 199, 1978.
277. Zimmerman, B.G., Blockade of adrenergic potentiating effects of angiotensin by 1-sar, 8-ala angiotensin, J. Pharmacol. Exp. Ther., 183, 486, 1973.
278. Feldberg, W. and Lewis, G.P., The action of peptides on the adrenal medulla. Release of adrenaline by bradykinin and angiotensin, J. Physiol., 171, 98, 1964.
279. Antonaccio, M.J. and Kerwin, L., Pre- and post-junctional inhibition of vascular sympathetic function by captopril in spontaneously hypertensive rats, Hypertension, 3 (I), 154, 1981.
280. Hatton, R. and Clough, D.P., Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms, J. Cardiovasc. Pharmacol., 4, 116, 1982.
281. Imai, Y., Abe, K., Seino, M., Haruyama, T., Tajima, J., Yoshinaga, K., and Sekino, H., Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II, Am. J. Cardiol., 49, 1537, 1982.
282. Mancia G., Parati, G., Pomidossi, G. et al., Modification of arterial baroreflexes by captopril in essential hypertension, Am. J. Cardiol., 6 (10), 791, 1988.
283. Cheng, S.W.T., Swords, B.H., Kirk, K.A., and Berecek, K.H., Effects of lifetime captopril treatment on baroreceptor function in the spontaneously hypertensive rat, Hypertension, 13, 63, 1989.
284. Cheng, S.W.T., Kirk, K.A., Robertson, J., and Berecek, K.H., Brain angiotensin II and baroreflex function in spontaneously hypertensive rats, Hypertension, 14, 274, 1989.
285. Casto, R. and Phillips, I., Angiotensin attenuates baroreflexes at nucleus solitarius of rats, Am. J. Physiol., R193, 1986.
286. Catt, K.J., Harwood, J.P., Aguilera, G., and Dufau, M.L., Hormonal regulation of peptide receptors and target cell responses, Nature, 280, 109, 1979.
287. +, Brain Res., 345, 54, 1985.
288. Bradshaw, B. and Moore, T.J., Abnormal regulation of adrenal angiotensin II receptors in spontaneously hypertensive rats, Hypertension, 11, 49, 1988.
289. Messenger, E.A., Stonier, C., and Aber, G.M., Differences in glomeruli binding and response to angiotensin II between normotensive and spontaneously hypertensive rats, Clin. Sci., 75, 191, 1988.
290. Matsushima, Y., Kawamura, M., Akabane, S., Imanishi, M., Kuramochi, M., Ito, K. and Omae, T., Increase in renal angiotensin II content and tubular All receptors in prehypertensive spontaneously hypertensive rats, Hypertension, 6 (10), 791, 1988.
291. Grammas, P., Diglio, C., Giacommeli, F., and Weiner, J., Cerebrovascular angiotensin II receptors in spontaneously hypertensive rats, J. Cardiovasc. Pharmacol., 13, 227, 1989.
292. Berecek, K.H., Swords, B.H., Lo, S., and Kirk, K.A., Effect of angiotensin converting enzyme inhibitors on brain angiotensin II binding, J. Hypertens., in press.